Identification of protective loss-of-function (LoF) mutations holds great promise for devising novel therapeutic interventions, although it faces challenges due to the scarcity of protective LoF alleles in the human genome. Exploiting the detailed mechanistic characterization of animal models of validated disease mutations offers an alternative. Here, we provide insights into protectivevariant biology based on our characterization of a model of the 22q11.2 deletion, a strong genetic risk factor for schizophrenia (SCZ). Postnatal brain up-regulation of Mirta22/Emc10, an inhibitor of neuronal maturation, represents the major transcriptional effect of the 22q11.2-associated microRNA dysregulation. Here, we demonstrate that mice in which the Df(16)A deficiency is combined with a LoF Mirta22 allele show rescue of key SCZ-related deficits, namely prepulse inhibition decrease, working memory impairment, and social memory deficits, as well as synaptic and structural plasticity abnormalities in the prefrontal cortex. Additional analysis of homozygous Mirta22 knockout mice, in which no alteration is observed in the above-mentioned SCZ-related phenotypes, highlights the deleterious effects of Mirta22 up-regulation. Our results support a causal link between dysregulation of a miRNA target and SCZ-related deficits and provide key insights into beneficial LoF mutations and potential new treatments.
LoF mutations | 22q11.2 microdeletion | Mirta22/Emc10 D espite substantial progress in the field of psychiatric genetics, the heterogeneity of genetic etiology and the corresponding neural complexity has rendered the task of understanding disease pathophysiology and developing improved treatments rather inauspicious (1) . In light of this complexity, there is need to identify convergent neural substrates and underlying molecular mechanisms that can serve as entry points to prevent or reverse disease progression. Along the same lines, identification of genetic mutations or variants that confer protection against disease via loss-offunction effects (LoF), akin to those of a therapeutic agent, hold great promise for devising therapeutic schemes (2) (3) (4) (5) to restore or prevent some or all disease symptoms, either in all patients or, more likely, in specific subsets of patients with well-defined genetic lesions of affected pathways. A well-established example is provided by studies of the PCSK9 locus, where therapeutic agents designed to inhibit PCSK9 were prospectively developed in response to the detected protective effects of PCSK9 LoF variants on LDL cholesterol levels and coronary artery disease risk (6, 7) . Similar success has increasingly been reported in other human diseases (8) (albeit not neuropsychiatric or neurodevelopmental disorders so far) and has prompted efforts to identify additional such advantageous LoF variants (9) . However, such studies face a number of challenges due to the scarcity of protective LoF alleles in the human genome, necessitating the use of exceedingly large cohorts of patients and healthy controls or resorting to either founder of consanguineous population, which are more likely to bear an excess of rare, functionally relevant protective variants (5) .
Another approach to identify such beneficial LoF mutations is to take advantage of animal models that accurately recapitulate validated pathogenic disease mutations. The detailed mechanistic characterization afforded in such model organisms could, in principle, identify genes or genetic pathways triggered by the primary mutation, whose LoF might lead to amelioration of disease severity and progression.
Here, using an extensively characterized animal model of the 22q11.2 deletion, one of the strongest known genetic risk factor for schizophrenia (SCZ) (10, 11) , we show that animal models of validated disease mutations can provide important insights into protective-variant biology. Specifically, previous research on the 22q11.2 deletions provided one of the strongest initial indications for a link between miRNA dysregulation and SCZ risk (12, 13) . A mouse model carrying a hemizygous 1.3-Mb chromosomal deficiency on chromosome 16 [Df (16) A], which is syntenic to the human 1.5-Mb 22q11.2 microdeletion, demonstrates abnormal processing and levels of brain miRNAs (12) . This miRNA dysregulation is due to hemizygosity of DGCR8, a component of the "microprocessor" complex that is essential for miRNA production, as well as hemizygosity of miRNA genes residing within the deletion, most notably mir185 (12, 14, 15) .
Significance
Despite substantial progress in the field of schizophrenia (SCZ) genetics, the heterogeneity of genetic etiology and neural complexity has rendered the task of developing improved treatments inauspicious. Thus, there is need to identify convergent neural substrates and underlying molecular mechanisms that can serve the prevention or reversal of disease progression. Our extensive characterization of an animal model of the 22q11.2 deletion, one of the strongest genetic risk factors for SCZ, when combined with a loss-of-function (LoF) mutation for a microRNA-dependent upregulated target, offers a proof of principle for such approaches. Hence, identification of variants that confer protection against disease by disabling protein function via LoF effects holds great promise for devising therapeutic schemes to restore or prevent disease symptoms.
Colocalization of DGCR8 and mir185 within the 22q11.2 locus results in a drastic reduction of the mir185 levels, greater than expected by the 50% decrease in genomic dosage, and results in a derepression of a previously unknown inhibitor of neuronal maturation, Mirta22 (Emc10), whose expression is partly under the control of mir185. Mirta22 is a prenatally biased gene with high expression in embryonic life that subsides after birth. Importantly, the end effect of 22q11.2-related derepression of Mirta22 expression is evident only in postnatal life in the form of a robust and reproducible increase in Mirta22 postnatal levels compared with wild-type (WT) mice (14) . Indeed, postnatal Mirta22 up-regulation is the major downstream transcriptional effect of the 22q11.2-associated miRNA dysregulation (14) , and, given that Mirta22 functions as an inhibitor of neuronal maturation, it may represent a key link in our understanding and manipulating of the chain of events leading from disease risk mutation to behavioral disturbance.
Df (16)A +/− mice show a distinct behavioral and cognitive profile, which includes central constructs affected in SCZ. Specifically, the mice exhibit hyperactivity, decrease in prepulse inhibition (PPI) that is indicative of sensorimotor gating deficits, working memory (WM) abnormalities, social memory (SM) deficits, and associative (fear) memory deficits (12) . In addition to the observed behavioral abnormalities, Df(16)A +/− mice also show alterations in the dendritic development of cortical neurons, as well as deficits in several forms of prefrontal cortical synaptic plasticity, which also emerge in part due to miRNA dysregulation (16) . If the sustained postnatal elevation of Mirta22 levels hinders normal development of circuits and behaviors, one prediction would be that LoF mutations of Mirta22 will have beneficial effects, preventing the emergence of at least some of these deficits.
In the present study, we show that genetic reduction of Mirta22 levels rescues key SCZ-related cognitive and behavioral dysfunctions present in the Df(16)A +/− mice, as well as several of the underlying synaptic and cellular deficits. Our results suggest that several key behavioral and physiological alterations observed in Df(16)A +/− mice can be attributed to the abnormally sustained inhibitory influence of elevated Mirta22 levels and highlight "protective" elements in the genetic and neural architecture of neuropsychiatric disorders.
Results
Restoration of Mirta22 Levels in the Df(16)A +/− Mice. We hypothesized that abnormally sustained high levels of Mirta22 in the postnatal brain are significant contributors to the phenotypic deficits observed in Df(16)A +/− mice. To test our hypothesis, we generated compound heterozygote mice in which the Df(16)A deficiency was combined with a LoF Mirta22 allele, resulting in the reduction of Mirta22 levels and near-normal restoration of its postnatal expression in several brain regions (SI Appendix, Fig.  S1 ). We used these mice to test whether reduction of Mirta22 levels and the accompanying relief from its inhibitory influences mitigate cognitive and behavioral dysfunctions present in the Df(16)A +/− mice and prevent several of the underlying synaptic and cellular deficits.
Restoration of Mirta22 Levels Prevents Deficits in PPI, WM-Dependent
Learning, and SM. Sensorimotor gating deficits in the form of PPI are frequently observed in patients with SCZ. PPI expression is regulated by a wide corticolimbic and brainstem network, upon which prefrontal cortex (PFC) exerts an important neuromodulatory role (17) (18) (19) (20) (21) . Although sensorimotor gating is not a cognitive process per se, it correlates well with several cognitive domains, such as executive function (22) , WM (23) (24) (25) , and social cognition (26) and likely shares neural substrates with these domains. We have previously shown that Df(16)A +/− mice exhibit a robust PPI deficit (12) . Analysis by genotype [repeated measures (RM) ANOVA, prepulse × genotype interaction F(12, 224) = 1.981, P = 0.027; main effect of genotype F(3, 56) = 8.308, P < 0.001] confirmed our previous result [Df (16) A +/− vs. WT, Bonferroni post hoc analysis, P < 0.0001; Fig. 1A Fig. S2 ). Thus, the PPI deficit observed in Df(16)A +/− mice can be attributed at least partially to the inhibitory influence of elevated Mirta22 levels.
WM is a primary cognitive domain frequently compromised in patients with SCZ, and its restoration is particularly resistant to antipsychotic medication. WM depends on the intact structure and short-and long-range communication, as well as local synaptic plasticity at the PFC (27) (28) (29) . A deficit in a T-maze version of the delayed nonmatch to sample task for WM is one of the most reproducible and reliable outcome measures in Df(16)A +/− mice, which exhibit a delay in acquiring the task (12, 30 (16)A +/− mice, but they benefited more from training and reached the learning criterion at the same pace as their WT littermates (SI Appendix, Fig. S3C ). Notably, similarly to PPI findings, Mirta22 +/− mice were indistinguishable from WT mice in their WM learning performance (SI Appendix, Fig. S3A ).
Deficits in social cognition represent another core symptom of SCZ psychopathology and a reliable predictor of functional outcome in patients (31, 32) . Although rodents do not display all features of human social cognition, and comparable information on cross-species circuit recruitment is scarce, use of rodent tasks that evaluate social cognition (33) can serve as a useful proxy of the human condition. By using a SM task for mice (34), we recently showed that Df(16)A +/− mice display a markedly impaired SM (35 
;Mirta22
+/− mice was further evident by the difference score (Fig. 1D) , which was fully restored to the WT levels [one-way ANOVA F(3, 60)=7.264, P < 0.0001; post hoc 
+/− vs. WT, P = 1.000]. In conclusion, disruption in social cognition, along with disruptions in sensorimotor gating and WM, is linked to Mirta22 derepression in the 22q11.2 mouse model of SCZ and is rescued by normalization of Mirta22 levels.
Normalization of Mirta22 Levels Fails to Rescue Hyperactivity and
Fear Memory Deficits. Hyperactivity in response to stress or novelty is widely used as a correlate of positive symptoms of SCZ in rodents, based on the notion that it could bear face validity for psychomotor agitation (36, 37) . Df(16)A +/− mice are hyperactive compared with WT littermates, shown by total path length traveled over a 1-h exposure period and hyperactivity on a subsequent 30-min reexposure 24 h later (12) . In the present study, Df(16)A +/− mice were found reproducibly hyperactive compared with WT mice (post hoc Bonferroni comparisons, day 1, P < 0.0001; day 2, P = 0.013) ( A marked deficit in contextual and cued fear memory is one of the most reproducible and reliable phenotypes observed in Df(16)A +/− mice (12) . This deficit likely reflects a readout of dysfunction in the neural circuit consisting of hippocampus (HPC), amygdala, and medial PFC (mPFC), all of which are involved in the learning and memory processes that promote adaptive context-dependent behavior (40, 41) , but whose relation to increased SCZ risk remains tenuous. We have previously shown that the fear memory deficit cannot be accounted for fully by global miRNA dysregulation in Dgcr8-deficient mice (12) . By subjecting mice to a fear-conditioning paradigm, we confirmed the fear memory deficit of the Df (16) 
;Mirta22
+/− mice, because these mice do not differ significantly from their WT littermates. Mirta22
+/− mice also demonstrated normal fear memory (Fig. 2C ). This result suggests that Mirta22 normalization, in brain areas known to modulate fear memory, such as PFC and amygdala (SI Appendix, Fig. S1 ), is not on its own sufficient to fully rescue contextual and cued fear memory deficits in Df (16) (Fig. 3) . This finding strongly suggests that altered PPI, WM, and SM in the Df(16)A +/− mice is directly linked to the elevation of Mirta22 levels above a permissive threshold indicated by the low physiological levels normally present in the postnatal brain.
Analysis of locomotor activity revealed that Mirta22 −/− mice traveled far less total distance compared with WT in the 1 h of OF testing on day 1 (P < 0.0001) and upon 30-min reexposure on day 2 (P < 0.0001) (Fig. 4A) . Notably, Mirta22
−/− mice showed a significant increase in locomotor habituation occurring 20 min after the beginning of OF testing on day 1, but unaltered activity levels up to that point [ 
+/− mice showed that they exhibited locomotor habituation comparable to the WT mice ( Fig. 2C ; RM ; and n = 13 for WT. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. , ns). Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
ANOVA, no significant genotype by time interaction), although they started and remained hyperactive most of the time during their initial 1-h exposure to OF (main genotype effect vs. WT, P = 0.009). Thus, hyperactivity in Df (16) ;Mirta22 +/− mice did not seem to be due to inability to habituate in a novel environment. This finding indicates that Mirta22 levels modulate locomotor habituation, a simple form of nonassociative learning (42) (43) (44) , rather than activity per se, explaining at least in part the inefficiency of Mirta22 down-regulation to rescue hyperactivity of the Df(16)A +/− mice. We also subjected Mirta22 −/− mice and their WT littermates to a fear-conditioning paradigm. WT freezing levels for contextual fear memory were somewhat lower than the ones observed in the same assay on Df(16)A +/− mice and their WT littermates (Fig.  2C) , but within the range reported in the literature (e.g., refs. 45 and 46). This result is likely due to differences in backcrossing generations (Materials and Methods), as well as differences in home cage microenvironment (47-49) that should similarly affect both genotypes. Analysis of fear learning revealed a marked effect of Mirta22 deficiency on associative memory, in which (Fig. 4D) . Mirta22 deficiency was not associated with increased baseline or postshock freezing levels, suggesting that any observed effects are specific to memory and not associated with increased anxiety or pain levels in the Mirta22 −/− mice, as verified with a pain sensitivity test (SI Appendix, Fig. S5B ). Also, freezing levels before presentation of the cue, during memory recall, were similar between Mirta22 −/− mice and their WT littermates, ruling out fear overgeneralization and pointing to the specificity of the cue memory. This result reveals a strong negative association between Mirta22 levels and associative fear memory. In that respect, the inability of Mirta22 down-regulation to fully prevent fear memory deficits in the Df(16)A +/− mice is quite surprising and likely points to a complicated interaction between Mirta22 overexpression and other genes removed by the 22q11.2 microdeletion, which results in rather intractable alterations in the neural circuits controlling fear learning. Interestingly, novel object recognition memory did not differ between WT and Mirta22 −/− mice (SI Appendix, Fig. S6 ), which was also unaffected in the Df(16)A +/− mice (16), pointing to the selectivity and specificity of altered Mirta22 expression on cognition.
Despite pointing to dissociable effects of up-regulation vs. down-regulation of Mirta22, together, our behavioral findings described above suggest that Mirta22 down-regulation, depending on the testing context and the overall genetic makeup, facilitates specific cognitive processes, such as WM, habituation to novelty, and associative emotional learning. 
+/− vs. WT, P = 1]. Given that fEPSPs obtained by using paired-pulse stimulation were not different among genotypes (SI Appendix, Fig. S7 ), the differences in synaptic strength at higher stimulation intensities could not be attributed to differences in the probability of neurotransmitter release at the L2-5 synapses. This result suggests that the rescue of fEPSP slopes in Df(16)A +/− ;Mirta22 +/− mice may arise from reinstatement of the number of functional synapses due to the normalization of spine density in L5 neurons (see below).
Df (16)A +/− mice also exhibit significantly higher fEPSP STD at high train stimulation, but normal neurotransmitter release, as assessed by a paired-pulse facilitation (PPF) protocol (16) . Here, we corroborated consistent deficits at 50 Hz, but we did not detect any difference between genotypes at lower (5 and 20 Hz) stimulation intensities (SI Appendix, Fig. S7C ). At 50 Hz [ Fig. 5B ; WT, 
+/− mice were rescued to WT levels (P = 0.559) and significantly improved compared with Df(16)A +/− mice (post hoc Bonferroni comparisons, P = 0.044). Overall, considering the central role that PFC synaptic plasticity plays in maintaining WM, the modulatory role that PFC has on sensorimotor gating, and the remarkable effect of Mirta22 reduction in preventing PFC synaptic plasticity alterations, it is tempting to speculate that the effect of Mirta22 normalization on improving synaptic plasticity deficits in the PFC contributes to the rescue of the PPI and WM deficits.
Reduction of Mirta22 Levels Prevents Structural Alterations in the mPFC of Df(16)A
+/− Mice. Given the effectiveness of Mirta22 down-regulation in preventing PFC synaptic plasticity deficits and our reported findings that normalization of Mirta22 expression prevents the emergence of structural alterations in CA1 hippocampal neurons (14), we asked whether such function is extended to the PFC, potentially contributing to the observed improvements in synaptic plasticity (Fig. 6 ). To analyze spine and dendrite morphology in L5 neurons in the prelimbic area of mPFC, we crossed Thy1-GFP +/− mice with Df (16) , and WT/GFP +/− littermates, which we used to assess basal dendrite morphology. This analysis confirmed previously reported structural abnormalities in terms of reduced spine density of Df (16) , ns]. Similar reversal on spine density deficits were observed in different types of spines as well, namely, long and filopodium (SI Appendix, Fig. S8 ).
Discussion
We demonstrate that the presence of a LoF Mirta22 allele in Df (16)A +/− mice, a mouse model of the SCZ-associated 22q11.2 microdeletion, where Mirta22 is up-regulated, is sufficient to prevent primary SCZ-related cognitive and behavioral deficits, along with underlying synaptic and structural plasticity alterations in the PFC. Because depletion of Mirta22 levels in Mirta22 knockout mice did not result in abnormalities in any of these behavioral phenotypes, the observed rescue likely reflects prevention of the deleterious effects of Mirta22 up-regulation in the context of the 22q11.2 locus.
Our results also suggest that failure of Mirta22 expression to subside into physiological levels at early postnatal life due to genomic loss at the 22q11.2 locus could be causally linked to the initiation of a chain of events, which prohibits neuronal circuits from attaining the degree of connectivity and plasticity that is necessary to subserve cognitive and behavioral faculties. In that respect, our work provides a comprehensive model of the consequences of altered miRNA regulation in Df(16)A +/− mice, attributed to the failure to restrict and optimize postnatal Mirta22 expression, a key breakdown in miRNA-dependent homeostatic regulation by the 22q11.2 genomic locus. This model is useful, offering a plausible synaptic and circuit explanation of 
Mirta22
+/− (n = 9), Df(16)A +/− (n = 8), and WT (n = 10). Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
one facet of the 22q11 microdeletion syndrome by crossing boundaries between multiple levels of analysis, providing a framework for future studies, and importantly pointing to several possible avenues for therapeutic interventions. Nonetheless, this model is still incomplete in its details. First, whether Mirta22 up-regulation impacts brain maturation during a critical stage of early postnatal synapse formation or whether abnormal sustained elevation of Mirta22 throughout the adult life interferes with ongoing synaptic communication and plasticity remains to be determined. Second, whether Mirta22 upregulation affects additional SCZ-related behaviors as well as neural circuitry in other brain regions (35) remains unknown. Although our synaptic plasticity and morphological assays point to the PFC, as an underlying substrate for our behavioral findings, it is very likely that Mirta22 up-regulation affects the fine structure and activity of other brain regions, including, for example, hippocampal area CA2, which plays a crucial role in social learning and is dysfunctional in Df(16)A +/− mice (27) . Along the same lines, the neural basis of the specificity of behavioral rescue also remains unknown. Given that Mirta22 is widely expressed in the brain (https://gtexportal.org/home/gene/EMC10; SI Appendix, Fig. S9 ) and its expression is similarly normalized in all three brain areas tested in Df (16) 
;Mirta22
+/− mice (SI Appendix, Fig. S1 ), this specificity is likely related to the way that the developmental pattern of Mirta22 expression is altered by the 22q11.2 miRNA dysregulation and how this alteration affects the postnatal maturation and function of brain areas subserving specific behavioral outputs. Third, our behavioral analysis used three cohorts of group-housed mice, with one of them subjected sequentially in three behavioral assays (Materials and Methods). Therefore, our behavioral findings should be interpreted in the context of the sequence and prior test history of the behavioral assays. However, all behaviors tested are robust and reproducible and have been previously observed in multiple cohorts independently of the testing history. Fourth, because only male mice were used in our analysis, it remains to be determined whether the beneficial effects of Mirta22 reduction encompass both sexes. Finally, the exact molecular and cellular mechanisms by which derepression of Mirta22 contributes to abnormal neuronal, synaptic, and circuit maturation remain unknown. The striking effect of normalization of Mirta22 levels may be linked to a possible role of MIrta22 in the elimination of misfolded membrane proteins as part of endoplasmic reticulum-associated degradation complex (60) . It may also be linked to a potential role of Mirta22 in membrane and protein trafficking and secretion related to its localization in Golgi apparatus and in vesicle and tubular-like extensions in dendrites and axons (14) . This process is located in the core of maturation and maintenance of neuronal connections and physiological levels of synaptic plasticity (61, 62) . It is also possible that, in its secreted form (63), Mirta22 interacts and interferes with neurotrophic or extracellular matrix factors known to mediate activity-dependent dendritic plasticity (64, 65) .
Disease risk conferred by large pathogenic copy number variants (CNVs) is likely due to the action of multiple risk genes. This hypothesis has been suggested both by our early work in mouse models of the 22q11.2 deletion (15) and by more recent human genetic studies, which showed that large CNVs contain multiple modest-effect risk genes (66) . Consistent with this view, Mirta22 is likely to act in concert with other genes within the 22q11.2 deletion that modulate either distinct phenotypes (such as hyperactivity or fear learning) that were not rescued by reduction of Mirta22 or overlapping phenotypes rescued by Mirta22 reduction. In the latter case, one example is Zdhhc8, which is also located in the Golgi apparatus, and is involved in membrane trafficking of neuronal proteins. Zdhhc8 deficiency affects some of the same behavioral (WM) and cellular phenotypes rescued by reduction of Mirta22 levels (67-69), in part by leading to hyperactive Gsk3 signaling and stunted growth of developing axonal terminals. Notably, we have recently shown that developmental inhibition of Gsk3 activity was also successful in rescuing WM and related neurophysiological deficits in the Df(16)A +/− mice (67, 69), pointing to more than one mechanism by which a pathogenic CNV affects a given behavior, as well as more than one entry point for therapeutic interventions. Our findings also offer more general insights into the genetic and neural architecture of psychiatric and neurodevelopmental disorders, in particular in the feasibility of implementing protectivevariant searches by exploiting data from well-characterized valid genetic disease models. A large number of relatively rare LoF variants that result in a nonfunctional or unstable gene product as well as potentially damaging missense variants have been identified in the human ortholog of Mirta22 (Emc10) gene (exac. broadinstitute.org/gene/ENSG00000161671) (70) . It is likely that such variants, when they cooccur with the 22q11.2 deletion, can confer protection against the risk, severity, or both of the 22q11.2-associated psychiatric and cognitive symptoms. Given the large numbers of affected 22q11.2 deletion carriers being required to generate sufficient discovery power, the resources required to test this prediction in humans are not currently available. It is also conceivable that other genetic lesions predisposing to SCZ also lead to up-regulation of Mirta22 activity or to aberrant repression of cellular processes where Mirta22 plays an important restraining role. The nature and prevalence of such mutations remains unknown, but it is plausible that impaired Mirta22 function may be beneficial in the context of additional mutations that predispose to psychiatric disorders. Along these lines, exploratory use of the sequence-kernel association test to test whether MIRTA22 (EMC10) variants confer protective effects (and therefore are underrepresented) in a publicly available SCZ cohort of modest size (SI Appendix) revealed a significant difference between cases and controls, indicating the existence of a small protective effect of MIRTA22 (EMC10) variants on SCZ risk. In support of this possibility, it was recently shown that 22q11.2 duplications, which result in reduced Mirta22 levels (14), might exert a protective effect in general SCZ risk (71, 72) . Again, given the considerable challenges in identifying rare protective LoF variants in common complex disorders such as SCZ, due to the rarity of these variants and the very large number of patients required (5), our results highlight the quintessential role that animal models may play in identifying such "advantageous" gene losses.
A major attraction of the inquiry for protective LoF variants is the potential for a novel therapeutic target roadmap. In that respect, the elucidation of the sequence of events that lead from the 22q11.2 deletion to cognitive and synaptic deficits, the demonstration that Mirta22 reduction can prevent emergence of some of these deficits, and the lack of any obvious adverse effects point to manipulation of Mirta22 expression as a potential treatment target. In that respect, it is remarkable that, unlike common antipsychotics, which ameliorate PPI but are minimally effective or completely ineffective in improving cognitive deficits, Mirta22 level regulation has been successful in reversing both PPI and two core SCZ cognitive deficits, such as WM and SM deficits. Furthermore, the similar developmental pattern of Mirta22 expression between mice (14), humans (SI Appendix, Fig. S10 ; Allen Brain Institute), and nonhuman primates (SI Appendix, Fig. S11 ; Allen Brain Institute), with a strong prenatal bias and a gradual decrease in expression with age, suggests a conserved mechanism of action and directly links our results in mice to possible treatment strategies in humans. Along these lines, in future experiments, it is important to determine when during the lifespan Mirta22 normalization is most effective at reversing behavioral and neurophysiological phenotypes and whether Mirta22 levels could be normalized by approaches as readily translatable into medical therapies as possible. These approaches include, for example, the application of siRNAs or shRNAs (73, 74) or the use of antisense oligonucleotides to inhibit excessive Mirta22 gene expression based on their efficacy in preclinical models (75, 76) and clinical studies (77, 78) of neurodevelopmental or neurodegenerative disorders. Alternatively, use of genome editing via CRISPR could be another highly promising approach for modulating Mirta22 function (79, 80) . Additionally, specific targeting of pathogenic or overexpressed forms of proteins has proven highly successful in cancer research and appears promising in the treatment of neurodegenerative disorders as well (81, 82) . This method is of particular interest in the case of Mirta22, because a secreted form of the protein has been found both in vitro and in human serum (14, 63) . Highly selective targeting of secreted Mirta22 in the brain (i.e., by monoclonal antibodies) could improve the behavioral and cognitive deficits associated with the 22q11.2 microdeletion. Furthermore, deciphering the function of Mirta22 and exploring its interactions with other neuronal molecular partners will provide insights into its specific role in neuronal processes and offer downstream targets for potential inhibition by specific pharmaceutical compounds. For such strategies to be successful, it will be important to determine the developmental window during which Mirta22 expression manipulations could be efficacious, because the diagnosis of SCZ is rarely made before late adolescence. Restricting the overexpression of Mirta22 in children carrying 22q11.2 deletions during early postnatal life will provide a framework for prevention, whereas its inhibition during adulthood could serve as an improved alternative or augmentation of current treatments because it might offer alleviation from cognitive deficits and psychotic symptoms.
If our findings eventually lead to novel treatments for the 22q11.2 deletion syndrome, it is unclear whether they will also apply to SCZ cases arising from other causes, given the high level of genetic heterogeneity of the disorder. The observation that Mirta22 down-regulation enhances specific aspects of cognitive functioning (i.e., novelty habituation and associative fear memory) even in a WT background, suggests that treatment interventions via inhibition of the product of this gene could be more generally applicable.
Overall, coupled with emerging ideas regarding beneficial LoF mutations, our results represent not only a decisive step toward a comprehensive understanding of the neurobiological consequences of the 22q11.2 deletions and the contribution of miRNA-dependent gene regulation to psychiatric and neurodevelopmental disorders, but also a decisive step toward translating these mechanistic insights into bona fide improvements in clinical management.
Materials and Methods
All procedures were conducted in accordance with NIH regulations and approved by Columbia University and New York State Psychiatric Institute Institutional Animal Care and Use Committees. ;Mirta22 +/+ (these are referred to as WT). Male offspring of all four genotypes, as well as male Mirta22 −/− and WT littermates, were used for behavioral testing. One cohort of mice was used for OF, PPI, and T-maze tasks, in that order; a separate cohort was used for SM assay; and a third cohort was used for the FC task. We also performed behavioral studies on three cohorts of Mirta22 −/− and WT littermates in a similar way: one cohort of mice for OF, PPI, and T-maze tasks, in that order; a separate cohort for SM assay; and a third cohort for the FC task. Male mice of Df (16) , and WT mice were used for cellular morphology analysis. Details on mouse numbers can be found in SI Appendix.
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Behavioral Testing. Behavioral phenotyping was performed as described (12) . The cerebellum and part of the HPC were removed, and coronal brain sections were cut on a vibratome (Leica VT1200S). The freshly cut mPFC slices were immediately transferred to an interface chamber and allowed to recover for at least 2 h at 34-36°C. During all recordings, the slices were continuously perfused with artificial CSF (aCSF) (bubbled with 5% CO 2 /95% O 2 ) that had the following composition (in mM): 124 NaCl, 2.5 KCl, 1 NaH 2 PO 4 , 25 NaHCO 3 , 10 glucose, 1 MgSO 4 , and 2 CaCl 2 . The aCSF was maintained at 34-36°C and fed by gravity at a rate of 2-3 mL/min. fEPSPs were recorded via a glass microelectrode (3-5 MΩ) filled with aCSF and placed in L5 of the mPFC (600-700 μm from midline).The stimulation site was always aligned ∼200 μm away from the recording site along the axis perpendicular to the pial surface. Basic synaptic transmission was characterized at 0.033 Hz, with stimulation intensities of 3-24 V (pulse duration, 0.1 ms). The subsequent experiments were performed at the stimulus intensity that generated a fEPSP one-third of the maximum fEPSP obtained at 24 V. Short-term synaptic facilitation was induced by using a paired-pulse protocol with interspike intervals of 20, 50, 100, 400, and 800 ms. To assess STD, fEPSPs were evoked by using a 40-pulse train at 5, 20, and 50 Hz (pulse duration, 0.1 ms). LTP was induced by 40 pulses, 50-Hz train after a stable 10-min baseline, and monitored during 15 min. Then, 15 min after the first tetanus, four additional 50-Hz trains (separated by 10 s) were applied. The fEPSPs were then monitored for 40 min. Signals were acquired by using the pClamp10 software (Molecular Devices), the Digidata 1440A (Molecular Devices), and an extracellular amplifier (Cygnus Technologies). Fiber volley was quantified by measuring the amplitude of the first peak negativity of the field responses, and the fEPSPs were quantified by measuring the initial slope of the second peak negativity of the responses. Statistical analyses were performed by using the SigmaPlot and Statview software. Data are presented as means ± SEM. N indicates number of animals, and n indicates number of slices. All recordings and the majority of data analyses were performed blind to the genotype. . Df(16)A +/− mice were crossed to the Thy1-GFP/M mouse line. Adult male littermates, at 2-3 mo of age, were anesthetized and transcardially perfused with 1× PBS, followed by 4% PFA in PBS. Brains were postfixed in 4% PFA and then sectioned coronally at 100 μm on a vibratome (Leica). Sections were mounted and images were obtained on a Carl Zeiss LSM 510 laser-scanning confocal microscope. The cortical layers were identified by NeuN immunostaining and Nissl staining (Invitrogen), and the cortical thickness was divided into seven bins (bin 1, marginal zone and L1; bin 2, L2; bin 3, L3; bins 4 and 5, L5; and bins 6 and 7, L6). L5 pyramidal neurons were almost exclusively labeled in the mPFC of the mice, throughout the cell body and the dendritic tree. Z stacks were acquired at higher magnification to facilitate the measurement of spine number, size, and morphology. A region of interest encompassing a segment of >50 μm from the first branch point of the largest dendrite was defined in one or two of the largest dendrites of the neuron. The bent-line overlay tool of LSM Image Examiner 5 was used to measure the length of the spine from the surface of the dendritic shaft, including the neck and head of the spine. The straight-line tool was used to measure the width of the spine at its widest point. Dendritic protrusions were categorized as spines or filopodia and morphologically classified as mushroom, long, stubby, or thin by using parameters described in ref. 68 . Specifically, spines with distinct heads were classified as "mushroom" if <2.0 μm or "long" if >2.0 μm. Spines without distinct heads were classified as "thin" if <2.0 μm or "stubby" if <1.0 μm but >0.35 μm. Protrusions without a distinct head and >2.0 μm were classified as filopodia.
Statistical Analysis. All behavioral and electrophysiology data were analyzed in SPSS with RM or one-way ANOVA with genotype as the factor and Bonferroni post hoc comparisons for the different genotypes. Data on the number, size, and shape of spines across conditions were analyzed with Student's t test, and the distribution of width of mushroom spines was compared by using the Kolmogorov-Smirnov test.
